Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.39 |
| ▸ | CTSD | P07339 | 2/20 | 0.38 |
| ▸ | CTSE | P14091 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569246 | 0.88 | NTSR1 (0.44) | APLNRNTSR1XIAPOPRD1CTSD | |
| SCHEMBL21312655 | 0.88 | POLB (0.41) | APLNRNTSR1XIAPOPRD1AGTR1 | |
| SCHEMBL29800934 | 0.87 | PTPN1 (0.42) | APLNRNTSR1XIAPOPRD1CTSD | |
| SCHEMBL31191376 | 0.86 | OPRD1 (0.47) | APLNRNTSR1OPRD1 | |
| SCHEMBL29800900 | 0.84 | NTSR1 (0.48) | NTSR1XIAPOPRD1PTPN1F2 | |
| SCHEMBL29399877 | 0.84 | NTSR1 (0.46) | APLNRNTSR1OPRD1PTPN1F2 | |
| SCHEMBL31067246 | 0.84 | PTPN1 (0.43) | APLNRNTSR1XIAPOPRD1AGTR1 | |
| SCHEMBL29801129 | 0.83 | PTPN1 (0.45) | APLNRNTSR1OPRD1PTPN1F2 | |
| SCHEMBL31191247 | 0.82 | OPRD1 (0.48) | NTSR1OPRD1PTPN1 | |
| SCHEMBL21516452 | 0.82 | KEAP1 (0.40) | APLNRNTSR1XIAPOPRD1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087138-A1 | AMINOMETHYL-FUNCTIONALIZED DENATONIUM DERIVATIVES, THEIR PREPARATION AND USE | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2021-03-25 | — | — | US | disclosed |
| WO-2019162289-A1 | AMINOMETHYL-FUNCTIONALIZED DENATONIUM DERIVATIVES, THEIR PREPARATION AND USE | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087138-A1 | AMINOMETHYL-FUNCTIONALIZED DENATONIUM DERIVATIVES, THEIR PREPARATION AND USE | F10, F11, HRH4 | APLNR 1895/4885NTSR1 1660/4885XIAP 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.